

uniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School

Lexington, MA and Amsterdam, the Netherlands, December 2, 2016 — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced its participation in two panel discussions at the 2016 Genetic Rx Conference taking place at the Harvard Medical School, in Boston, MA, on December 8, 2016.

Both Harald Petry, Ph.D. and Christian Meyer, MD, Ph.D. are among several industry leaders to co-host the Genetic Rx Conference and each also will participate in the following panel discussions:

➤ **Key Collaborations with Academia**

Participating: Harald Petry, PhD – Chief Scientific Officer

Time slot: Thursday, December 8th, 2:15 p.m. EST

➤ **Engaging Regulators, When and How?**

Participating: Christian Meyer, MD, PhD – Chief Medical Officer

Time slot: Thursday, December 8th, 3.30 p.m. EST

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the implementation and effects of the Company's new strategic and organizational changes, the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with corporate reorganizations and strategic shifts, collaboration arrangements, our and our collaborators' clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

Maria E. Cantor

Direct: 339-970-7536

Mobile: 617-680-9452

m.cantor@uniQure.com

Eva M. Mulder

Direct: +31 20 240 6103

Mobile: +31 6 52 33 15 79

e.mulder@uniQure.com

Tom Malone

Direct: 339-970-7558

Mobile: 339-223-8541

t.malone@uniQure.com